|
Okyo Pharma Ltd - London-headquartered biotechnology company - Intends to file a investigational new drug filing to the US Food & Drug Administration of OK-101 for the treatment of dry eye disease, scheduled for the fourth quarter of 2022.
From then on, the first human trial is designed as a phase two trial is expected to begin in the first quarter of 2023.
AmbioPharm will support the OK-101 program through peptide synthesis and development.
‘We are absolutely delighted to have AmbioPharm, a global leader in the synthesis of peptides and peptide analogs, manufacturing our drug candidate OK-101. The work performed by Ambiopharm during this post-Covid 19 period to keep us on schedule with the manufacture of API went above and beyond the call of duty and was a testament to the high standards that AmbioPharm abides by,’ says Chief Executive Officer Gary Jacob.
Current stock price: 2.60 pence
12-month change: down 47%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
